Threshold: WHO-CHOICE proxy 1x PDB Rp 75 juta/QALY; 3x PDB Rp 225 juta/QALY (not an official InaHTAC threshold).
Primary comparator is macular laser photocoagulation because it is the pragmatic, JKN-reimbursable Indonesian standard of care for DMO and the NICE TA274 base comparator; off-label bevacizumab is included as the cheap real-world class-context comparator most relevant to LMIC practice and tested in scenario analysis.
DMO is the chosen indication (over wet AMD / RVO) because Indonesia carries one of the world's highest diabetic-retinopathy burdens (Asia range up to ~43%) on top of ~19.5 million people with diabetes, making DMO the largest anti-VEGF-eligible ophthalmic population.
NICE TA274 recommends ranibizumab for DMO only where central retinal thickness is >=400 micrometres and at a patient-access-scheme discount; this analysis adopts the >=400 micrometre cost-effective subgroup as the modelled population.
Ranibizumab (Lucentis) is BPOM-registered (NIE DKI0767506043A1, Novartis) and also supplied as the LMIC formulation Patizra; precise current Fornas/JKN listing and any restriction wording for anti-VEGF agents in DMO should be verified directly against the current Kepmenkes Formularium Nasional, which could not be confirmed from official text in this review.
A ranibizumab biosimilar and lower-priced anti-VEGF options materially change affordability and are tested in scenario analysis; the within-class value question (ranibizumab vs off-label bevacizumab) is the central budget-impact issue for Indonesia.